Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?

Table 2

Therapeutic and postoperative characteristics. Discrete data are given as numbers, continuous as the mean ± standard deviation.

Parameter	Value
Total number of patients	77
Neoadjuvant chemotherapy
EC/DOC	61 (79.2%)
TAC	11 (14.2%)
Others	5 (6.4%)
Endocrine therapy	—
Neoadjuvant targeted therapy
Trastuzumab	15 (19.4%)
Lapatinib	3 (3.8%)
Trastuzumab + pertuzumab	2 (2.5%)
Bevacizumab	6 (7.7%)
None	51 (66.2%)
Posttherapeutic sonographic tumor diameter (mm)	12.6 ± 10.0
Postoperative histologic tumor diameter (mm)	15.7 ± 17.1
Postoperative tumor stage
0	20 (25.9%)
1a	9 (11.6%)
1b	7 (9%)
1c	18 (23.3%)
2	15 (19.4%)
3	6 (7.7%)
4	2 (2.5%)
Grade of regression (Sinn)
0	3 (3.8%)
1	28 (36.3%)
2	22 (28.5%)
3	2 (2.5%)
4	18 (23.3%)
Unknown	4 (5.1%)